Your browser doesn't support javascript.
loading
Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles
Bayo, J; Fonseca, PJ; Hernando, S; Servitja, S; Calvo, A; Falagan, S; García, E; González, I; Miguel, MJ de; Pérez, Q; Milena, A; Ruiz, A; Barnadas, A.
Afiliación
  • Bayo, J; Hospital Juan Ramón Jiménez. Huelva. Spain
  • Fonseca, PJ; Hospital Universitario Central de Asturias. Spain
  • Hernando, S; Fundación Hospital Alcorcón. Alcorcón. Spain
  • Servitja, S; Hospital del Mar. Barcelona. Spain
  • Calvo, A; Hospital La Princesa. Madrid. Spain
  • Falagan, S; Fundación Hospital Alcorcón. Alcorcón. Spain
  • García, E; Corporació Sanitaria I Universitaria Parc Taulí. Sabadell. Spain
  • González, I; Hospital del Mar. Barcelona. Spain
  • Miguel, MJ de; Hospital Universitario Virgen del Rocío. Sevilla. Spain
  • Pérez, Q; Hospital Universitario Central de Asturias. Asturias. Spain
  • Milena, A; Hospital Universitario A Coruña. Madrid. Spain
  • Ruiz, A; Hospital Juan Ramón Jiménez. Huelva. Spain
  • Barnadas, A; Hospital de la Santa Creu I Sant Pau. Barcelona. Spain
Clin. transl. oncol. (Print) ; 14(6): 413-422, jun. 2012.
Article en En | IBECS | ID: ibc-126809
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
Chemotherapy-induced nausea and vomiting (CINV) is a major determinant of quality of life in cancer patients. In addition, the perceptions that oncology professionals have about CINV quite often do not coincide with reality. Antineoplastic agents and their combinations can be categorised according to their emetogenic level, and this categorisation is helpful for classifying the severity of CINV and treating it. All CINV treatment guidelines emphasise the need to administer prophylaxis to patients who receive highly or moderately emetogenic chemotherapy. With the introduction of NK1 receptor antagonists, the control of acute and delayed CINV after highly or moderately emetogenic chemotherapy schedules has improved in the great majority of patients. NK1 receptor antagonists have been demonstrated to improve the control of CINV in all risk subgroups of patients (AU)
Asunto(s)
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Vómitos / Náusea / Antineoplásicos Tipo de estudio: Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2012 Tipo del documento: Article
Buscar en Google
Añadir a Mi BVS
Imprimir
XML
Colección: 06-national / ES Base de datos: IBECS Asunto principal: Vómitos / Náusea / Antineoplásicos Tipo de estudio: Guideline Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2012 Tipo del documento: Article